Virginia Del. Kathy Tran (D) says her bill to to require more accountability from 340B hospitals was prompted by The New York Times' investigation of alleged 340B program misuse detrimental to a Richmond hospital in a predominantly Black neighborhood.
A Virginia House subcommittee is voting later today on a Democrat’s bill to require more accountability from 340B hospitals—a direct consequence of The New York Times’ exposé about alleged 340B program misuse involving a Richmond, Va., hospital.
“It’s not hyperbole to say if this is put into place, we’re going to have to cut services and cut staffing," Mark Malahosky of Trillium Health says of New York State's plan to shift Medicaid managed care prescription drug benefits into Medicaid fee for service.
With a two-year implementation delay nearly over, New York State is poised to fold its Medicaid managed care prescription drug benefits into its Medicaid fee for service system on April 1. State 340B health care providers that serve
U.S. Rep. Brett Guthrie (left) (R-Ky.) will chair the Energy & Commerce Subcommittee on Health and Rep. Morgan Griffith (R-Va.) the Subcommittee on Oversight and Investigations.
U.S. House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-Wash.) yesterday as expected announced that Rep. Brett Guthrie (R-Ky.) will chair the Subcommittee on Health and Rep. Morgan Griffith (R-Va.) the Subcommittee on Oversight and Investigations.
U.S. Rep. Matt Rosendale (R-Mont.) has reintroduced a bill to put a moratorium on 340B hospital growth, impose 340B reporting requirements on hospitals, and make it harder for private nonprofit hospitals to stay in 340B.
A new U.S. House bill would put a moratorium on 340B hospital growth and impose a host of reporting requirements on 340B hospitals. It would also make it much harder for private nonprofit hospitals to remain in the
The composition of the House Energy & Commerce Committee in this Congress is clear now that party leaders have agreed on committee sizes and ratios.
U.S. House Speaker Kevin McCarthy (R-Calif.) and Minority Leader Hakeem Jeffries (D-N.Y.) have reached an agreement on the balance of power in committees during this Congress and are expected to formally assign members to committees as soon as
Astellas says the old and new NDCs for its antifungal drug Cresemba are interchangeable in compliant 340B inventory replenishment models.
Drug manufacturer Astellas will let 340B covered entities using “a compliant 340B inventory replenishment model” count accumulations of its antifungal Cresemba under its old National Drug Code toward replenishment of equal quantities under the product’s corresponding new NDC,
Policymakers should consider disbanding the 340B program, a student and a professor at the Stanford University School of Medicine say in the New England Journal of Medicine.
Policymakers should consider disbanding the 340B program “given its negative reverberations for patients and markets,” a student and a professor at the Stanford University School of Medicine wrote in a commentary in the latest edition of the New
MedPAC thinks CMS should stop using the Medicare DSH patient percentage for Medicare purposes. The 340B program uses the DSH calculation for hospital eligibility purposes.
The Medicare Payment Advisory Commission, as expected, has voted to recommend that Congress should start phasing in a new way of distributing extra Medicare payments to safety net hospitals that disproportionately serve low-income and/or uninsured beneficiaries.
RWC-340B is dropping is lawsuit that helped prod HRSA to issue long-delayed 340B dispute resolution rules.
Ryan White Clinics for 340B Access is dropping its lawsuit that, together with a related case, led federal health officials to issue long-delayed dispute resolution rules for the 340B program in December 2020.
Pennsylvania rescinded a new Medicaid policy document that said contract pharmacies could not dispense 340B-purchased drugs to Medicaid beneficiaries.
The Pennsylvania Department of Human Services yesterday rescinded Medicaid policy guidance dated Dec. 22 and effective Jan. 1 that forbade 340B covered entities’ contract pharmacies from dispensing 340B-purchased drugs to Medicaid beneficiaries.
